Medicamen Biotech has signed a contract for CDMO with XGX pharma, European company where Medicamen will develop 6 products and will do manufacturing of these products for European company. XGX will hold MA (Market authorisation).
Earlier, the company had entered into an understanding with a prominent South African business conglomerate for registering and marketing its products in the region. South Africa represents a $4 billion pharmaceutical market and is categorized as a regulated market.
Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1935.25 |
| Dr. Reddys Labs. | 1245.50 |
| Cipla | 1438.75 |
| Zydus Lifesciences | 1150.50 |
| Lupin | 2496.05 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: